Search the Newsreel

Champions Oncology, Inc. Revenue Breakdown – NASDAQ:CSBR

Champions Oncology, Inc. (NASDAQ: CSBR) generated $59.42 million in revenue last year, primarily from its Pharmacology Services segment, which contributed $57.13 million. The majority of this revenue, $59.42 million, came from operations within the United States. This represents an increase from the previous year's …

Champions Oncology Q4 Earnings Call Highlights

Champions Oncology (CSBR) reported record revenue of $59.4 million for fiscal 2026, driven by its Translational Oncology Solutions business, and achieved positive adjusted EBITDA in all four quarters. The company saw services revenue increase by 12% to $58.7 million, with improved gross margins due …

CSBR Stock Dips Post Q4 Earnings Despite Record Revenue Growth, AI Push

Champions Oncology (CSBR) shares dipped by 10.9% following its Q4 earnings report, despite record revenue growth in fiscal 2026 driven by its core research services. The company experienced an operating loss for the full year but saw narrowed diluted losses per share and improved …

Is Champions Oncology (NASDAQ:CSBR) In A Good Position To Invest In Growth?

Champions Oncology (NASDAQ:CSBR) has a cash runway of approximately 12 months based on its current cash burn of US$5.0m and cash reserves of US$4.9m as of April 2026. While this short runway is a concern, its revenue grew by 4.4% last year, and its …

Champions Oncology Inc (CSBR) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Champions Oncology Inc (CSBR), noting its current valuation score of 8.90 within the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of -31.65, which is significantly below its recent high and above its …

Champions Oncology Inc (CSBR) Financial Health: Profitability & Balance Sheet Analysis

Champions Oncology Inc (CSBR) currently has a financial score of 8.72, ranking 31st out of 384 in the Biotechnology & Medical Research industry, indicating a weak financial status despite high operating efficiency. The company's latest quarterly revenue decreased by 2.82% year-over-year to 16.56M, while …

Tranche Update on Champions Oncology, Inc.'s Equity Buyback Plan announced on April 5, 2023.

Champions Oncology, Inc. provided a tranche update on its equity buyback plan announced on April 5, 2023. From February 1, 2026, to April 30, 2026, the company did not repurchase any shares. However, since the plan's inception, the company has completed the repurchase of …

CHAMPIONS ONCOLOGY, INC. FY 2026: Revenue $59.43M, EPS ($0.08) — 10-K Summary

Champions Oncology, Inc. reported fiscal year 2026 revenue of $59.43 million, a 4.4% increase from the prior year, driven by higher pharmacology services and conversion of delayed studies. Despite revenue growth, the company experienced a net loss of ($1.18M) and diluted EPS of ($0.08), …

Champions Oncology Reports Record Annual Revenue of $59 Million

Champions Oncology, Inc. announced record annual revenue of $59.4 million for fiscal year 2026, alongside its fourth consecutive quarter of positive Adjusted EBITDA. The company highlighted significant progress in strategic priorities, including expanding its radiopharmaceutical platform and strengthening its data strategy, which it believes …

Champions Oncology reports record $59.4M revenue, positive adjusted EBITDA for FY2026

Champions Oncology (CSBR) reported record fiscal year 2026 revenue of $59.4 million and positive adjusted EBITDA of $1.6 million for the full year. Despite these gains, the company posted a net loss due to continued investments in radiopharmaceuticals, its data platform, and commercial expansion. …

At fiscal year-end, Champions Oncology had $4.9M cash, no debt

Champions Oncology (CSBR) reported record fiscal 2026 revenue of $59.4 million, up 4% year-over-year, despite missing prior-year data license revenue. The company ended the fiscal year with $4.9 million in cash and no debt, while achieving positive Adjusted EBITDA in all four quarters. Operating …

Champions Oncology Inc (CSBR) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Champions Oncology Inc (CSBR), outlining major institutional and individual holdings. It lists the top shareholders, the proportion of shares held by different investor types, and historical institutional shareholding data. The data indicates significant holdings by Battery Management …

Champions Oncology (NASDAQ:CSBR) Releases Earnings Results, Hits Estimates

Champions Oncology earnings beat by $0.06, revenue topped estimates

Champions Oncology Inc (CSBR) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Champions Oncology Inc (CSBR) dividend and stock split history, indicating that no dividend data is available for the past five years. It also includes current stock price information and market capitalization for CSBR. The content appears to be …

Champions Oncology Inc (CSBR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a brief overview of Champions Oncology Inc (CSBR), including its stock performance and market cap. It highlights that detailed revenue breakdown data by business segment and region has not yet been disclosed by the company, though it lists United States revenue …

Enterprise value to EBITDA forward of Champions Oncology, Inc. – MUN:2I3

The article discusses the Enterprise Value to EBITDA forward for Champions Oncology, Inc. (MUN:2I3) as traded on the Munich Stock Exchange. It appears to be a financial data point from a TradingView search, indicating a specific valuation metric for the company. The content itself …

Champions Oncology, Inc. Revenue Breakdown – MUN:2I3

Champions Oncology, Inc. (MUN:2I3) generated €50.28 million in revenue last year, primarily from its Pharmacology Services segment (€42.90 million), a decrease from the previous year. The majority of this revenue, €50.28 million, came from the United States, compared to €47.03 million in the prior …

Champions Oncology Inc (CSBR) Institutional Confidence

Champions Oncology Inc (CSBR) has an institutional shareholding score of 3.00, placing it 192nd out of 386 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 47.97%, showing a quarter-over-quarter decrease of 7.89%. James Simons is the largest institutional shareholder, …

Champions Oncology (CSBR) Q2 2026 Earnings: EPS Misses Estimates as Stock Gains 2.17% - EBITDA Analysis

CSBR|Champions Oncology Inc|Price:6.130|Chg%:+0.140

TradingKey provides a comprehensive stock analysis of Champions Oncology Inc (CSBR), highlighting its stable fundamentals, high growth potential, and fair valuation within the Biotechnology & Medical Research industry. The company's stock has high institutional ownership and analysts have set a price target of $12.00, …

Champions Oncology Inc (CSBR) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Champions Oncology Inc (CSBR), focusing on its price momentum, support and resistance levels, and various technical indicators and moving averages. As of July 24, 2026, CSBR's price momentum score is 4.07, and it is trading between resistance …

CSBR vs. CTKB: Which Life Sciences Stock Has Better Long-Term Upside?

This article compares Champions Oncology, Inc. (CSBR) and Cytek Biosciences, Inc. (CTKB), two life sciences companies, to determine which offers better long-term upside. While CSBR focuses on oncology research services and is expanding into data-driven businesses, CTKB specializes in cell analysis instruments and is …

Zacks Initiates Coverage of Champions Oncology With Neutral Recommendation

Zacks Investment Research has initiated coverage of Champions Oncology (CSBR) with a "Neutral" recommendation, citing the company's notable strides in drug discovery despite industry challenges. While Champions Oncology's core business shows momentum with record study services revenues and positive adjusted EBITDA, its long-term growth …

Champions Oncology (CSBR.US) will release its earnings report after market close on July 27.

Champions Oncology (CSBR.US) is scheduled to release its earnings report after market close on July 27. This announcement indicates an upcoming financial disclosure for the company. Investors will be anticipating the report to assess the company's performance.

Champions Oncology to announce Q4 and FY26 results on July 27

Champions Oncology, Inc. will release its financial and operational results for the quarter and fiscal year ended April 30, 2026, after market close on Monday, July 27, 2026. The company will also host a conference call on the same day at 4:30 P.M. ET …

Champions Oncology Schedules Year-End Results Call for 4:30 p.m.

Champions Oncology (NASDAQ: CSBR) announced it will report its financial and operational results for the fourth quarter and year ended April 30, 2026, on Monday, July 27, 2026, after market close. The company will host a conference call on the same day at 4:30 …

Enterprise value to EBITDA forward of Champions Oncology, Inc. – SWB:2I3

This article from TradingView provides financial information for Champions Oncology, Inc. (SWB:2I3), specifically focusing on its enterprise value to EBITDA forward. It indicates that the company is listed on the Stuttgart Stock Exchange and presents various financial metrics and community insights within the platform.